Tira exclusively launches Korean skincare brand Dr. Melaxin in India

Reliance Retail-backed beauty platform Tira has brought South Korean dermo-cosmetic brand Dr. Melaxin to India, selling its Peel Shot range online and through select stores as it deepens its premium K-beauty offer.

— FiledTue, 21 Jul, 2026, 18:02 IST·First seen Tue, 21 Jul, 2026, 18:01 IST·Source Fortune India

What happened

Reliance Retail-backed beauty platform Tira has exclusively launched South Korean dermo-cosmetic brand Dr. Melaxin in India online and at select stores, led by

Key facts

  • July 21, 2026
  • 17:52 IST
  • 8-FREE

Why this matters

Dr. Melaxin’s India entry via Tira highlights the strategic value of exclusive distribution deals for global beauty brands seeking rapid access to India’s premium skincare market.

What to watch

  • Dr. Melaxin sell-through, replenishment frequency and repeat-purchase rates within the first 90-180 days.
  • Expansion beyond Peel Shot into sunscreen, barrier repair, pigmentation or anti-aging SKUs.
  • Number of Tira stores carrying the brand and whether it gains prominent in-store consultation or display space.
  • Influencer-led demand spikes, review sentiment and any backlash around peel/active-ingredient suitability for Indian skin types.
  • New K-beauty exclusive announcements from Tira, Nykaa, Sephora India or Tata CLiQ Palette.
  • Discounting intensity: sustained full-price sales would signal premium brand traction; early markdowns would indicate weak product-market fit.
  • Add dermatologist education, creator seeding and before-after content around the Peel Shot range to translate K-beauty novelty into efficacy-led demand.
  • Use Tira loyalty and Reliance customer data to target premium skincare buyers, acne/pigmentation shoppers and existing Korean beauty customers with trial bundles.
  • Expand the brand from select stores into high-income metro doors if repeat rates and consultation-led conversion meet thresholds.
  • Seek adjacent Korean dermocosmetic and scalp-care exclusives to build a coherent clinical K-beauty destination rather than a one-brand launch.
  • Competitors are likely to respond with accelerated K-beauty onboarding, exclusive drops and price-led discovery kits.